Cue Biopharma, Inc. Forecast, price target & analysts
$0.78
2.52%
Nasdaq,
Apr 21, 10:00 pm CET
Cue Biopharma, Inc. Target price 2025 - Analyst rating & recommendation
Powered by
Cue Biopharma, Inc. Classifications & Recommendation:
Buy
100%
Cue Biopharma, Inc. Price Target
| Target Price | $2.00 |
| Price | $0.78 |
| Potential |
156.02%
register free of charge
|
| Number of Estimates | 2 |
|
2 Analysts have issued a price target Cue Biopharma, Inc. 2026 .
The average Cue Biopharma, Inc. target price is $2.00.
This is
156.02%
register free of charge
$2.00
156.02%
register free of charge
$2.00
156.02%
register free of charge
|
|
| A rating was issued by 2 analysts: 2 Analysts recommend Cue Biopharma, Inc. to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Cue Biopharma, Inc. stock has an average upside potential 2026 of
156.02%
register free of charge
|
Sales and Margin forecast 2025, 2026 & 2027
Create a premium account to unlock analyst estimates.
Learn more
Powered by
Quarter
Annually
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 9.29 | 4.88 |
| 69.22% | 47.52% |
2 Analysts have issued a sales forecast Cue Biopharma, Inc. 2025 . The average Cue Biopharma, Inc. sales estimate is
$4.9m
Unlock
47.52%
lower
Unlock
$9.8m
4.96%
Unlock
$0.0
100.00%
Unlock
This results in the following potential growth metrics:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027
Create a premium account to unlock analyst estimates.
Learn more
Powered by
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| EV/Sales | 6.88 |
Based on analysts' sales estimates for 2025, the Cue Biopharma, Inc. stock is valued at an EV/Sales of
6.88
Unlock
9.66
Unlock
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 3.61 | 61.39% |
|---|---|---|
| 2025 |
6.88
90.50%
Unlock
|
|
P/S ratio
| Current | 5.07 | 67.30% |
|---|---|---|
| 2025 |
9.66
90.55%
Unlock
|
|
Cue Biopharma, Inc....
Current Cue Biopharma, Inc. Upgrades & Downgrades
Create a Premium account to unlock Upgrades/Downgrades.
Learn more
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Citizens Capital Markets |
Locked
➜
Locked
|
Locked | Apr 02 2025 |
| Stifel |
Locked
➜
Locked
|
Locked | Aug 20 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Citizens Capital Markets:
Locked
➜
Locked
|
Apr 02 2025 |
|
Locked
Stifel:
Locked
➜
Locked
|
Aug 20 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
